durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['durva', 'aegean']
the #oncoalerttoptweet day 3 #aacr23 tweet by aegean phase 3 trial with perioperative durvalumab+ neoadj chemo presented by dr. heymach at #aacr23 49% n2+, efs nr vs 25.9 mo (hr 0.68, p 0.0039), 24-mo efs 63% vs 52% (median fup 11.7 mo, 31.9% maturity), 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨